loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Glufosfamide

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Glufosfamide

    ACTIVE PHARMA INGREDIENTS

    PRICE INFORMATION

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 101,450Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Eleison to Partner China Oncology Focus an Affiliate of Lee’s for Glufosfamide
    Eleison to Partner China Oncology Focus an Affiliate of Lee’s for Glufosfamide

    21 Nov 2017

    // PRESS RELEASE

    http://www.eleison-pharma.com/cushy_uploads/news_32_4097612997.pdf

    PRESS RELEASE
    21 Nov 2017
    Share Share
    Eleison Announces Approval from CFDA to Expand Eleison’s PhIII Glufosfamide
    Eleison Announces Approval from CFDA to Expand Eleison’s PhIII Glufosfamide

    16 May 2016

    // PRESS RELEASE

    http://www.eleison-pharma.com/cushy_uploads/news_30_1180908512.pdf

    PRESS RELEASE
    16 May 2016
    Share Share
    Eleison Announces the Issuance of New Patents for Glufosfamide and ILC
    Eleison Announces the Issuance of New Patents for Glufosfamide and ILC

    11 Dec 2015

    // PRESS RELEASE

    http://www.eleison-pharma.com/cushy_uploads/news_29_2036342757.pdf

    PRESS RELEASE
    11 Dec 2015
    Share Share
    Eleison Announces Agreement with FDA on a SPA for a Ph3 Glufosfamide
    Eleison Announces Agreement with FDA on a SPA for a Ph3 Glufosfamide

    26 May 2010

    // PRESS RELEASE

    http://www.eleison-pharma.com/cushy_uploads/news_5_2316371766.pdf

    PRESS RELEASE
    26 May 2010
    Share Share